题名 | Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. |
链接 | http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(14)60845-X.pdf |
欢迎光临 科研速递论坛 (http://expaper.cn/) | Powered by Discuz! X2.5 |